Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C2250> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- NCIT_C2250 IAO_0000115 "A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types." @default.
- NCIT_C2250 NCIT_A32 NCIT_C1909 @default.
- NCIT_C2250 NCIT_A7 NCIT_C17191 @default.
- NCIT_C2250 NCIT_NHC0 "C2250" @default.
- NCIT_C2250 NCIT_P106 "Organic Chemical" @default.
- NCIT_C2250 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C2250 NCIT_P107 "Pralatrexate" @default.
- NCIT_C2250 NCIT_P108 "Pralatrexate" @default.
- NCIT_C2250 NCIT_P207 "C0879404" @default.
- NCIT_C2250 NCIT_P210 "146464-95-1" @default.
- NCIT_C2250 NCIT_P319 "A8Q8I19Q20" @default.
- NCIT_C2250 NCIT_P322 "CTRP" @default.
- NCIT_C2250 NCIT_P322 "FDA" @default.
- NCIT_C2250 NCIT_P322 "GDC" @default.
- NCIT_C2250 NCIT_P325 "A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor." @default.
- NCIT_C2250 NCIT_P329 "37828" @default.
- NCIT_C2250 NCIT_P330 "37828" @default.
- NCIT_C2250 NCIT_P366 "_10-Propargyl-10-Deazaaminopterin" @default.
- NCIT_C2250 NCIT_P375 "Pralatrexate" @default.
- NCIT_C2250 NCIT_P399 "37828" @default.
- NCIT_C2250 normalizedInformationContent "92.730304365937428" @default.
- NCIT_C2250 referenceCount "3" @default.
- NCIT_C2250 hasExactSynonym "(2S)-2-[[4-[(1RS)-1-[(2, 4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic Acid" @default.
- NCIT_C2250 hasExactSynonym "10-Propargyl-10-Deazaaminopterin" @default.
- NCIT_C2250 hasExactSynonym "10-propargyl-10-deazaaminopterin" @default.
- NCIT_C2250 hasExactSynonym "FOLOTYN" @default.
- NCIT_C2250 hasExactSynonym "Folotyn" @default.
- NCIT_C2250 hasExactSynonym "N-(4-{1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic Acid" @default.
- NCIT_C2250 hasExactSynonym "PDX" @default.
- NCIT_C2250 hasExactSynonym "PRALATREXATE" @default.
- NCIT_C2250 hasExactSynonym "Pralatrexate" @default.
- NCIT_C2250 hasExactSynonym "pralatrexate" @default.
- NCIT_C2250 inSubset NCIT_C116977 @default.
- NCIT_C2250 inSubset NCIT_C116978 @default.
- NCIT_C2250 inSubset NCIT_C128784 @default.
- NCIT_C2250 inSubset NCIT_C157711 @default.
- NCIT_C2250 inSubset NCIT_C157712 @default.
- NCIT_C2250 inSubset NCIT_C176424 @default.
- NCIT_C2250 inSubset NCIT_C177537 @default.
- NCIT_C2250 inSubset NCIT_C63923 @default.
- NCIT_C2250 type Class @default.
- NCIT_C2250 isDefinedBy ncit.owl @default.
- NCIT_C2250 label "Pralatrexate" @default.
- NCIT_C2250 subClassOf NCIT_C186664 @default.
- NCIT_C2250 subClassOf NCIT_C1908 @default.
- NCIT_C2250 subClassOf NCIT_C1909 @default.
- NCIT_C2250 subClassOf NCIT_C2153 @default.
- NCIT_C2250 subClassOf NCIT_C2250 @default.
- NCIT_C2250 subClassOf NCIT_C272 @default.
- NCIT_C2250 subClassOf NCIT_C274 @default.
- NCIT_C2250 subClassOf NCIT_C471 @default.
- NCIT_C2250 subClassOf NCIT_C511 @default.